Post-earnings recap
Reported
Thu, Feb 19, 2026
EPS actual
$-1.67
EPS est.
$-0.21
EPS surprise
-699.04%
1-day move
+1.41%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
PTC Therapeutics reported a significant loss per share, which was not unexpected as no revenue figures were disclosed. Despite the disappointing EPS, the stock rose by 1.41%, possibly due to investor optimism about ongoing clinical trials and product development. The lack of guidance may leave investors cautious about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.67 | N/A | -699.04% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious approach due to the lack of revenue updates. They emphasized the importance of their clinical programs.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on ongoing clinical trials and product development.